trending Market Intelligence /marketintelligence/en/news-insights/trending/3mcz09vzkjlbqrefzbsvag2 content esgSubNav
In This List

Novo Nordisk chairman, CFO to step down

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novo Nordisk chairman, CFO to step down

Novo Nordisk A/S said that its chairman and CFO will both step down.

Chairman of the board Göran Ando decided not to seek re-election at the company's annual general meeting in March. Helge Lund has been recommended by the board to replace him.

Jesper Brandgaard will step down as CFO, effective Feb. 15. Karsten Munk Knudsen, currently senior vice president of corporate finance, will succeed him.

Brandgaard will continue as executive vice president responsible for biopharm and legal affairs.

The Danish pharmaceuticals giant was recently bested by Sanofi in its bid for Belgium-based Ablynx NV.